150 related articles for article (PubMed ID: 37172528)
1. The clinicopathological significance of TOP2A expression in malignant peritoneal mesothelioma.
Du X; Li X; Zhang B; Hao Z; Gao Y; Jiang X; Yang Z; Chen Y
Ann Diagn Pathol; 2023 Aug; 65():152155. PubMed ID: 37172528
[TBL] [Abstract][Full Text] [Related]
2. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters.
Türkcü G; AlabalIk U; Keles AN; Ibiloglu I; Küçüköner M; Sen HS; Büyükbayram H
Pol J Pathol; 2016 Jun; 67(2):108-13. PubMed ID: 27543864
[TBL] [Abstract][Full Text] [Related]
3. Loss of NPM2 expression is a potential immunohistochemical marker for malignant peritoneal mesothelioma: a single-center study of 92 cases.
Wu HL; Yang ZR; Su YD; Ma R; Du XM; Gao Y; Li Y
World J Surg Oncol; 2022 Oct; 20(1):350. PubMed ID: 36280841
[TBL] [Abstract][Full Text] [Related]
4. MUC1 has prognostic significance in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Int J Biol Markers; 2013 Sep; 28(3):303-12. PubMed ID: 23828409
[TBL] [Abstract][Full Text] [Related]
5. Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma.
Chen Y; Du X; Gao Y; Wu H; Zhao H; Su Y
Cancer Control; 2023; 30():10732748231220805. PubMed ID: 38092371
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
7. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
8. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma.
Pillai K; Pourgholami MH; Chua TC; Morris DL
Am J Clin Oncol; 2015 Aug; 38(4):388-94. PubMed ID: 26214083
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors influencing survival in 35 patients with malignant peritoneal mesothelioma.
Kaya H; Sezgı C; Tanrıkulu AC; Taylan M; Abakay O; Sen HS; Abakay A; Kucukoner M; Kapan M
Neoplasma; 2014; 61(4):433-8. PubMed ID: 24645844
[TBL] [Abstract][Full Text] [Related]
11. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
12. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Deraco M; Cabras A; Baratti D; Kusamura S
Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
[TBL] [Abstract][Full Text] [Related]
13. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Expression of Aquaporin-1 in Fluoro-Edenite-Induced Malignant Mesothelioma: A Preliminary Report.
Angelico G; Caltabiano R; Loreto C; Ieni A; Tuccari G; Ledda C; Rapisarda V
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495596
[TBL] [Abstract][Full Text] [Related]
16. Clinical-pathological characteristics and prognostic factors for malignant peritoneal mesothelioma in the elderly.
Pan D; Wang M; Liu W; Li Y; Sang L; Chang B
BMC Gastroenterol; 2022 Jun; 22(1):292. PubMed ID: 35681152
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
18. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
[TBL] [Abstract][Full Text] [Related]
19. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009.
Jennings CJ; Walsh PM; Deady S; Harvey BJ; Thomas W
Cancer Epidemiol; 2014 Feb; 38(1):35-41. PubMed ID: 24394956
[TBL] [Abstract][Full Text] [Related]
20. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
[Next] [New Search]
